Navigation Links
Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting
Date:11/17/2010

RICHMOND, Calif., Nov. 17, 2010 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of Phase 2 clinical data from its ZFP Therapeutic program to develop SB-509, a zinc finger protein transcriptional activator (ZFP-TF) of the vascular endothelial growth factor (VEGF)-A gene as a treatment for ALS. The data from study SB-509-801 demonstrated that the drug was well-tolerated in subjects with ALS and that 40% of SB-509 treated subjects had delayed deterioration of toe and ankle muscle strength as measured by manual muscle testing (MMT) compared to 23% of baseline-matched historic controls.  In addition, positive improvements in electrophysiological measures of motor nerves were observed in a subset of treated subjects.  The data were presented at the Society for Neuroscience Annual Meeting which is being held in San Diego.  

"These data are consistent with the delay in muscle deterioration that we have observed in both preclinical models of ALS as well as in clinical studies of this drug in subjects with diabetic neuropathy, a condition that is also characterized by degeneration and deterioration of nerve function," stated Dale Ando, M.D., Sangamo's vice president of therapeutic development and chief medical officer. "Our primary aim in this trial was to assess safety and tolerability of treatment with SB-509 in this vulnerable patient population and to conduct a signal-seeking study in which we assessed the effect of treatment on several clinical measures of function in ALS.  As this was an early-stage trial, for safety reasons we treated subjects twice over a 90 day period, although our positive preclinical animal data were achieved with a more frequent dosing schedule.  With that said, the delayed deterioration in muscle strength in the ankle and toe are very encouraging and may reflect the importa
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Sangamo BioSciences Announces Presentation at Lazard Capital Markets Healthcare Conference
2. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant Human Stem Cells
3. Sangamo BioSciences Receives Michael J. Fox Foundation Funding to Develop Novel Drug for the Treatment of Parkinsons Disease
4. Sangamo BioSciences Announces First Quarter 2010 Conference Call and Webcast
5. Sangamo BioSciences Announces Fourth Quarter and Full Year 2009 Conference Call and Webcast
6. Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium
7. Sangamo Announces Closing of Common Stock Offering
8. Sangamo BioSciences Announces Research Collaboration With UCLA in Human Stem Cells Selected to Receive Clinical Research Award
9. Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
10. Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech
11. Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... , July 23, 2014 Research and ... "Disposable Medical Gloves (Exam and Surgical) Markets Worldwide 2014" ... http://photos.prnewswire.com/prnh/20130307/600769 The purpose of this ... for Disposable Medical (Exam and Surgical) Gloves. The report ... for these products. Topics covered include product ...
(Date:7/23/2014)... 2014  Nearly 8,000 attendees will converge in ... Retail Business Conference (RBC), taking place July 23-26 at ... event encourages pharmacists to "Lead Change" in the pharmacy ... for their future. "RBC is the ... their peers and learn new ways they can lead ...
(Date:7/23/2014)... -- The management team at Columbia Laboratories, Inc. (Nasdaq: ... call on July 31, 2014, to discuss financial ... 2014.  The call details are as follows:Date: , ... numbers: , Toll free: (877) 870-4263 (U.S.), (855) ... , www.columbialabs.com , under ,Investor, or ...
Breaking Medicine Technology:Disposable Medical Gloves (Exam and Surgical) Markets Worldwide 2014 2Disposable Medical Gloves (Exam and Surgical) Markets Worldwide 2014 3Disposable Medical Gloves (Exam and Surgical) Markets Worldwide 2014 4Cardinal Health Encourages Independent Pharmacists to Lead Change at 24th Annual Retail Business Conference 2Cardinal Health Encourages Independent Pharmacists to Lead Change at 24th Annual Retail Business Conference 3Cardinal Health Encourages Independent Pharmacists to Lead Change at 24th Annual Retail Business Conference 4Cardinal Health Encourages Independent Pharmacists to Lead Change at 24th Annual Retail Business Conference 5Cardinal Health Encourages Independent Pharmacists to Lead Change at 24th Annual Retail Business Conference 6Columbia Laboratories to Discuss Second Quarter 2014 Financial Results on July 31st Conference Call 2
... BURLINGTON, Vt ., June 4 Mach 7 Technologies ... has relocated its global headquarters from suburban Chicago to ... the company,s base for Americas, sales and professional service operations, and ... and strategic R&D functions. , ...
... June 4 /PRNewswire-Asia-FirstCall/ -- Jiangbo,Pharmaceuticals, Inc. (OTC Bulletin Board: JGBO) ... China , today,announced that the Company has received approval to list its ... , , ... will begin trading on the NASDAQ,Global Market on Tuesday, June 8, ...
Cached Medicine Technology:Mach 7 Technologies Establishes New Headquarters in Burlington, VT 2Jiangbo Pharmaceuticals, Inc. Receives Approval to List on the NASDAQ Global Market 2Jiangbo Pharmaceuticals, Inc. Receives Approval to List on the NASDAQ Global Market 3
(Date:7/23/2014)... The National Quality Forum’s (NQF) Board ... for a defined period that will assess the ... measures for sociodemographic factors, prior to making a ... can be socioeconomic, e.g., income, education, and occupation, ... Growing evidence shows that sociodemographic factors may ...
(Date:7/23/2014)... 23, 2014 In preparation for National ... Millennium Treatment Group is providing tips on choosing a ... society ever since man first figured out the process ... has existed since shortly thereafter. Its basis lies in ... then developing a way to combat that problem while ...
(Date:7/23/2014)... Steven Reinberg HealthDay ... -- Many obese and overweight American children and teens ... is fine, U.S. health officials reported Wednesday. "Being ... such as high blood pressure, high cholesterol and diabetes," ... the U.S. Centers for Disease Control and Prevention,s National ...
(Date:7/23/2014)... Inventor and entrepreneur Delegate Joe T. ... the gas pump – sharing his passion for technology ... at Noon. , With 24 patents granted and three ... anyone in the General Assembly since Thomas Jefferson. Inventions ... marker as seen on television, an instrument for measuring ...
(Date:7/23/2014)... WHAT: The National Institute of Biomedical Imaging and ... Investigator Symposium on July 30, 2014 on the NIH ... new investigators covering a wide breadth of NIBIB-funded research. ... Adam Cohen, Harvard, Engineering Microbial Rhodopsins as Optical Voltage ... Testing Fluorescently Labeled Probes for Nerve ...
Breaking Medicine News(10 mins):Health News:NQF Board Approves Trial Period to Test Impact of Risk Adjustment of Performance Measures for Sociodemographic Factors 2Health News:Millennium Treatment Group Offers Tips on Choosing a Reputable Treatment Center 2Health News:Millennium Treatment Group Offers Tips on Choosing a Reputable Treatment Center 3Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 2Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 3Health News:Celebrating Innovation and Invention 2
... UK, US and Canada are undermining tobacco prevention campaigns by ... public health researchers says. The paper, published in the open ... tobacco imagery should be ineligible for public funding to ensure ... goals. Earlier research shows that young people who are ...
... Aug. 23 (HealthDay News) -- Researchers say boys are ... that males have been reaching sexual maturity about 2.5 ... "The reason for earlier maturity for ... disease environments are getting more favorable for it," demographer ...
... 2011 In a joint research effort with researchers ... from scientists at The University of Pennsylvania, The University ... from the Florida campus of The Scripps Research Institute ... to rid themselves of damaged mitochondria, which are the ...
... in a new study a different approach to predict ... other similar chemicals. For many chemicals in ... to understand all of the effects on the environment ... Union enacted the REACH regulation, which places greater responsibility ...
... the University of Toronto,s psychology department show that ... Botox injections or surgery are viewed more negatively than ... facial creams and younger adults are more negative about ... suggest that despite the rapid growth of the anti-aging ...
... most frequent type of malignant brain tumor in children. Ependymoma ... hollow cavities of the brain. Therapy results of ependymoma vary ... standstill after surgery and radiotherapy, in other children the disease ... affected the tumor continues to grow and the patients often ...
Cached Medicine News:Health News:Government subsidies to the US film industry promote youth smoking, argue researchers 2Health News:Boys Mature Sexually Earlier Than Ever Before: Study 2Health News:Scripps Research scientists define cellular pathway essential to removing damaged mitochondria 2Health News:Scientists develop new approaches to predict the environmental safety of chemicals 2Health News:U of T research shows anti-aging techniques not yet viewed as acceptable 2Health News:Brain tumors found to have a 2-tier system 2
Round handle colibri tying forceps with 5 mm titanium coated platforms. Length 100 mm....
Barraquer straight tying forceps....
Round handle curved tying forceps with 5 mm titanium coated platforms. Length 110 mm....
Colibri tying forceps with 5 mm titanium coated platforms. Length 85 mm....
Medicine Products: